Clinical abuse potential study - MORPHABOND ER VS MS CONTIN

Clinical abuse potential study—Intranasal: MORPHABOND ER VS MS Contin®

MORPHABOND ER Was Significantly Less Liked vs MS Contin® if Manipulated and Taken Intranasally1,2

 

Mean Drug Liking Over Time

Primary Endpoint: Mean Maximum Drug Liking (Emax) for crushed intranasal MORPHABOND ER vs crushed intranasal MS Contin® was 71.7 vs 85.3 (P<0.0001)

76%

of subjects (n=19) experienced reduced Drug Liking with crushed intranasal MORPHABOND ER vs crushed intranasal MS Contin®

Subjects Were Less Willing to Take MORPHABOND ER Again vs MS Contin® if Manipulated and Taken Intranasally1

 

Mean Take Drug Again

 
MORPHABOND ER retains its extended-release properties even if manipulated
Abuse of MORPHABOND ER is still possible by intranasal, intravenous, and oral routes

Study design: The intranasal abuse potential and relative bioavailability of MORPHABOND ER was evaluated in a randomized, double-blind, double-dummy, placebo-controlled, single-dose, 4-way crossover study in 25 nondependent recreational opioid users comparing crushed intranasal MORPHABOND ER 60 mg, crushed intranasal MS Contin® 60 mg, and intact oral MORPHABOND ER 60 mg.

  • Primary endpoint: mean maximum effect (Emax) for drug liking between crushed intranasal MORPHABOND ER and crushed intranasal MS Contin®
  • Secondary comparisons for the primary endpoint included Emax for intact oral MORPHABOND ER compared with crushed intranasal MS Contin® and crushed intranasal MORPHABOND ER
  • Other secondary endpoints included Take Drug Again assessments and determining the relative bioavailability of morphine in plasma for crushed intranasal and intact oral MORPHABOND ER compared with crushed intranasal MS Contin®
  • Drug Liking (primary) and Take Drug Again (secondary) endpoints were measured on a 100-mm bipolar visual analog scale (VAS) where 50 represents a neutral response, 0 represents the strongest negative response, and 100 represents the strongest positive response

MORPHABOND ER VS MS CONTIN Navigation